Penumbra Q2 revenue slightly beats estimates, helped by product segment increase

Penumbra

30/07/2026 21:13

Overview
Thrombectomy device maker's Q2 revenue rose 14.9% yr/yr, slightly beating analyst expectations
Q2 net income fell to $34.8 mln from $45.3 mln a year earlier
Company incurred $6.9 mln in acquisition-related expenses amid pending Boston Scientific deal

Outlook
Company will not provide full-year 2026 financial guidance due to pending acquisition

Result Drivers
PRODUCT SEGMENT GROWTH - Embolization and access revenue rose 20% yr/yr, while thrombectomy revenue increased 12.5%
GEOGRAPHIC PERFORMANCE - U.S. revenue grew 17.1% yr/yr, outpacing international growth of 7.6%
ACQUISITION-RELATED EXPENSES - Co incurred $6.9 mln in expenses tied to pending Boston Scientific acquisition

Company press release: ID:nPn3xFn92a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$390.05 mln
$389.009 mln (16 Analysts)
Q2 Net Income
 
$34.81 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Penumbra Inc is $374.00, about 16.8% above its July 29 closing price of $320.13
The stock recently traded at 56 times the next 12-month earnings vs. a P/E of 61 three months ago

Reuters Recommended Reads
July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength
July 29 - Conmed Q2 sales, adjusted profit beat on organinc platform growth
July 29 - FDA panel votes against Capricor's Duchenne heart disease therapy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)